| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| Other Sizes |
| Targets |
Pipercide acts on the nervous system of insects, specifically inducing repetitive discharge on the central nerve cord. This neurotoxic mechanism disrupts normal neural signaling, leading to paralysis and death of the target insect. The compound's primary molecular targets are likely ion channels or neurotransmitter receptors in the insect nervous system, though the precise binding targets have not been fully elucidated. As an amide alkaloid, it may interact with voltage-gated sodium channels or other neuronal membrane proteins.
|
|---|---|
| ln Vitro |
In vitro studies have demonstrated that pipercide exhibits potent larvicidal activity against mosquito larvae. Based on 48-hour LC₅₀ values, pipercide was the most toxic compound tested against Culex pipiens pallens larvae with an LC₅₀ of 0.004 ppm. It also showed high larvicidal activity against Aedes aegypti, Aedes togoi, and Culex pipiens pallens. Pipercide demonstrated remarkable insecticidal activity against the adzuki bean weevil, with potency comparable to pyrethrin.
|
| ln Vivo |
In vivo insecticidal activity of pipercide has been demonstrated in various insect models. Topical application of pipercide to adult adzuki bean weevils resulted in significant mortality. Oral and topical administration of pipercide to Lymantria dispar and Malacosoma disstria larvae showed significant toxicity. The compound also exhibited activity against adult female mosquitoes of Culex pipiens pallens and Aedes aegypti. These in vivo studies confirm pipercide's potential as an effective insecticide for pest control applications.
|
| Enzyme Assay |
Standard insecticidal activity assays are used to evaluate pipercide. For larvicidal activity, late third or early fourth instar mosquito larvae are placed in cups containing water with various concentrations of the test compound. Mortality is recorded after 24-48 hours. LC₅₀ values are calculated by Probit analysis. For topical application assays, adult insects are treated with a microdroplet of compound solution applied to the dorsal thorax using a microapplicator. Mortality is assessed at 24-72 hours post-treatment.
|
| Cell Assay |
For in vitro cell-based studies, insect cell lines such as Sf9 (Spodoptera frugiperda) or Drosophila Schneider 2 cells may be used to evaluate cytotoxicity and neurotoxic effects. Cells are cultured in appropriate media and exposed to serial dilutions of pipercide. Cell viability is assessed using MTT or resazurin assays. Electrophysiological recordings using patch-clamp techniques on isolated insect neurons can be employed to study the compound's effects on neural excitability and repetitive discharge induction.
|
| Animal Protocol |
In vivo animal studies for pipercide typically involve insect pest models rather than mammalian models. For mosquito larvicidal assays, larvae are maintained in dechlorinated water at 25-28°C and fed with yeast or fish food. Test compounds are dissolved in acetone or DMSO and added to the water. Mortality is recorded at 24 and 48 hours. For topical application studies on adult beetles or weevils, insects are anesthetized with CO₂ and treated with compound solutions using a microsyringe.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of pipercide have not been extensively characterized. As a lipophilic amide with a molecular weight of 355.47 g/mol, it is expected to have good membrane permeability. The compound has a density of 1.066 g/cm³ and a boiling point that suggests moderate volatility. Specific PK parameters such as absorption, distribution, metabolism, and excretion in mammals have not been reported. Further pharmacokinetic studies are needed to understand its behavior in biological systems.
|
| Toxicity/Toxicokinetics |
Toxicological data for pipercide are limited in the published literature. The compound is primarily studied as an insecticide, and its toxicity to mammals has not been comprehensively evaluated. Acute toxicity studies in non-target organisms would be necessary for environmental risk assessment. As a natural product from black pepper, it may have a relatively favorable safety profile compared to synthetic insecticides. However, systematic toxicological evaluation is required for potential applications.
|
| References |
|
| Additional Infomation |
Piperidine is a member of the benzodioxane group of compounds. It has been reported to exist in plants of the genus Piper (such as Piper mullesua), Piper eucalyptifolium, and other organisms with relevant data.
Pipercide is a research compound with insecticidal applications. No clinical trials or therapeutic uses have been reported for this compound. It has been identified in various Piper species and is used as a reference standard for natural product research. The compound's potent larvicidal activity makes it a candidate for development as a botanical insecticide. Structure-activity relationship studies of pipercide and related amides may guide the development of new insecticidal agents. |
| Molecular Formula |
C22H29NO3
|
|---|---|
| Molecular Weight |
355.47056
|
| Exact Mass |
353.199
|
| CAS # |
54794-74-0
|
| PubChem CID |
5372162
|
| Appearance |
Typically exists as solid at room temperature
|
| Density |
1.066g/cm3
|
| Boiling Point |
573.1ºC at 760 mmHg
|
| Melting Point |
114 - 115 °C
|
| Flash Point |
300.4ºC
|
| Index of Refraction |
1.559
|
| LogP |
5.489
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
10
|
| Heavy Atom Count |
26
|
| Complexity |
496
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CC(C)CNC(=O)\C=C\C=C\CCCC\C=C\c1ccc2OCOc2c1
|
| InChi Key |
RPOYGOULCHMVBB-ADDDGJNWSA-N
|
| InChi Code |
InChI=1S/C22H29NO3/c1-18(2)16-23-22(24)12-10-8-6-4-3-5-7-9-11-19-13-14-20-21(15-19)26-17-25-20/h6,8-15,18H,3-5,7,16-17H2,1-2H3,(H,23,24)/b8-6+,11-9+,12-10+
|
| Chemical Name |
(2E,4E,10E)-11-(1,3-benzodioxol-5-yl)-N-(2-methylpropyl)undeca-2,4,10-trienamide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.8132 mL | 14.0659 mL | 28.1318 mL | |
| 5 mM | 0.5626 mL | 2.8132 mL | 5.6264 mL | |
| 10 mM | 0.2813 mL | 1.4066 mL | 2.8132 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
